| II-34 Yu-wei Lin Utilizing model informed drug development to support study design for Tovorafenib (DAY101), a novel, type II, pan RAF kinase inhibitor: a focus on longitudinal safety markers Wednesday 15:10-16:40 |
| II-34 Yu-wei Lin Utilizing model informed drug development to support study design for Tovorafenib (DAY101), a novel, type II, pan RAF kinase inhibitor: a focus on longitudinal safety markers Wednesday 15:10-16:40 |